AVITA Downgraded by Piper Sandler Over Sales Outlook
Piper Sandler: The AVITA Medical (RCEL.US) rating was lowered from an increase in holdings to a neutral rating, and the target price was adjusted from $21.00 to $9.00.
Analysts Offer Insights on Healthcare Companies: Avita Medical (RCEL), Inotiv (NOTV) and Hims & Hers Health (HIMS)
AVITA Medical Analyst Ratings
Cantor Fitzgerald Maintains Overweight on AVITA Medical, Lowers Price Target to $21
Piper Sandler Reaffirms Their Hold Rating on Avita Medical (RCEL)
Steady Performance and Promising Outlook: A Buy Rating for Avita Medical
Piper Sandler Downgrades Avita Medical to Neutral From Overweight, Price Target Is $9
Analysts Offer Insights on Healthcare Companies: Avita Medical (RCEL) and CVRx (CVRX)
Wilsons Downgrades Avita Medical to Market-Weight From Overweight; Price Target Is AU$3.03
Lake Street Keeps Their Buy Rating on Avita Medical (RCEL)
BTIG: Downgraded AVITA Medical (RCEL.US) rating from buy to neutral.
AVITA Medical Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), Disc Medicine (IRON) and Avita Medical (RCEL)
TD Cowen Keeps Their Buy Rating on Avita Medical (RCEL)
Piper Sandler Raises Price Target on Avita Medical to $21 From $19, Maintains Overweight Rating
AVITA Medical Analyst Ratings
Piper Sandler Sticks to Its Buy Rating for Avita Medical (RCEL)
Avita Medical Poised for Growth: Strong Q4 Performance and Promising 2024 Outlook Reinforce Buy Rating
Buy Rating Affirmed for Avita Medical on Strong Financials and Expansive Growth Strategy
No Data